JAN 0 3 2007

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act 4 295

Complete if Known Substitute for form 1449/PTO Application Number 10/578,013 Filing Date INFORMATION DISCLOSURE May 3, 2006 STATEMENT BY APPLICANT First Named Inventor Robert F. Garry Art Unit 1648 (Use as many sheets as necessary) **Examiner Name Attorney Docket Number** Sheet 1 of 1 12920.0013.PCUS00

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/NK/	C1	ATABANI, et al., Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection, Journal of Virology, 1997, 71(10):7240-7245.	
/NK/	C2	SAMUEL, et al., Participation of two fusion peptides in measles virus-induced membrane fusion: emerging similarity with other paramyxoviruses, Biochemistry, 2001, 40:1340-1349.	
/NK/	СЗ	KLIGER, et al., Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy, BMC Microbiology, 2003, 3:20.	
			,
	·		

Examiner Signature	/Nicole Kinsey/	Date Considered	11/16/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN 0 9 2007

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
as are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/578,013			
Filing Date	May 3, 2006			
First Named Inventor	Robert F. Garry			
Art Unit	1648			
Examiner Name				
Attorney Docket Number	12920.0013.PCUS00			

			U. S. PATENT	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NK/	A1	^{US-} 5,464,933	11-07-1995	Bolognesi et al.	
1.	A2	^{US-} 5,567,805	10-22-1996	Henderson et al.	
V	A3	US- 5,747,239	05-05-1998	Wang et al.	
/NK/	A4	^{US-} 6,037,348	03-14-2000	Colacino et al.	
		US-			
1112		US-			
		US-			

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if knawn)	MM-DD-YYYY	,,	Or Relevant Figures Appear	
/NK/	B1	WO 2005/010034 A1	02-03-2005	Natl Institutes of Health		
/NK/	B2	WO 2005/016238 A2	02-24-2005	Duke University		
						L
						L

1	Examiner	/Nicole Kinsev/	Date	11/16/2007	
ı	Signature	/Nicole Kinsey/	Considered	11/10/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

							Page 1 of 1		
Form P	TO-144	9 (modified)		Atty. Docket No. 12920.0013.PCUS00		Serial No. 10/578,013			
Ē		nd Publications for A		nt's Applicant Robert F. Garry, Russell B. Wilson					
NFORMATION DISCLOSURE STATEMEN				Filing Date:		Group:			
(2007	2007 (Use several sheets if necessary)			May 3, 2006		1648			
U.S. Patent Documents See Page 1			-	Patent Documents See Page 1		Other Art See Pages 1			
			U.S. Pate	ent Documen	ts				
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.		
	Al								
	A2								
	A3								
	A4					<u>. </u>			
	Foreign Patent Documents								
Exam. Init.	Ref. Des	Document Number	Date	Country	Class	Sub Class	Translation Yes/No		
/NK/	B3	WO 01/59457 A2	08/16/2001	WIPO	G01N	33/569			
/NK/	B4	WO 88/08429	11/03/1988	WIPO	C07K	7/08			
(Other Art (Including Author, Title, Date Pertinent Pages, Etc.)								
Exam. Init.	Ref. Des.	Citation							
/NK/	C4	CHAN, et al., Evid attractive drug targ	lence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an et, (1998). Proc. Natl. Acad. Sci. USA 95, 15613-15617.						
/NK/ hemagglutinin, (1993). <i>Cell</i> 73 , 823-8				ng-loaded mechanism for the conformational change of influenza 3). Cell 73, 823-832.					
				virus envelope protein reveals structural similarity to Current Biology 5, 1377-1383.					

DATE CONSIDERED: 11/16/2007 **EXAMINER:** /Nicole Kinsey/

CLEGG, et al., Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and

comparative analysis of arenavirus gene products, (1991). Virus Research 18, 151-164.

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

C7

/NK/